Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.59 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.59 |
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 4/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | TAF1 | P21675 | 1/20 | 0.37 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.37 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30548029 | 1.00 | TNF (0.59) | TNFRIPK1ARGPR84AHR | |
| SCHEMBL30548032 | 1.00 | TNF (0.59) | TNFRIPK1ARGPR84AHR | |
| SCHEMBL29713816 | 0.77 | TNF (0.42) | TNFRIPK1ARAHRBRD4 | |
| SCHEMBL6097464 | 0.77 | TNF (0.42) | TNFRIPK1ARAHRBRD4 | |
| SCHEMBL2537028 | 0.77 | TNF (0.63) | TNFRIPK1ARGPR84AHR | |
| SCHEMBL30260939 | 0.77 | TNF (0.63) | TNFRIPK1ARGPR84AHR | |
| SCHEMBL16091101 | 0.76 | TNF (0.50) | TNFRIPK1ARGPR84AHR | |
| SCHEMBL31677511 | 0.76 | TNF (0.61) | TNFRIPK1ARGPR84AHR | |
| SCHEMBL18876104 | 0.75 | TNF (0.46) | TNFRIPK1ARGPR84AHR | |
| SCHEMBL21863271 | 0.74 | TNF (0.59) | TNFRIPK1ARGPR84AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230127-A1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2025-07-17 | — | — | US | disclosed |
| US-12172959-B2 | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2024-12-24 | — | — | US | disclosed |
| CN-113045476-B | Monosubstituted or disubstituted indole derivatives as dengue virus replication inhibitors | 杨森制药公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240182414-A1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2024-06-06 | — | — | US | disclosed |
| US-11827602-B2 | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2023-11-28 | — | — | US | disclosed |
| CN-111303000-B | Monosubstituted or disubstituted indole derivatives as dengue virus replication inhibitors | 杨森制药公司 | 2023-11-28 | — | — | CN | disclosed |
| US-11827602-B2 | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827602-B2 | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2023-11-28 | — | — | US | disclosed |
| WO-2023114472-A1 | HETEROCYCLIC COMPOUNDS AS 5HT2A BIASED AGONISTS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-06-22 | — | — | WO | disclosed |
| EP-3896072-B1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2022-11-16 | — | — | EP | disclosed |
| US-6329366-B1 | HETEROCYCLIC, PIPERIDINE, INDOLE DERIVITIVES FOR TREATMENT OF NERVOUS SYSTEM DISORDERS AND SEROTONIN ANTAGONIST | ELI LILLY AND COMPANY LIMITED (GB) | 2001-12-11 | — | — | US | disclosed |
| WO-2001087881-A1 | PIPERIDYINDOLES AS SEROTONIN RECEPTOR LIGANDS | ELI LILLY AND COMPANY (US) | 2001-11-22 | — | — | WO | disclosed |
| EP-1131321-A2 | INDOLE DERIVATIVES AND THEIR USE AS SEROTONIN RECEPTOR LIGANDS | ELI LILLY AND COMPANY LIMITED (GB) | 2001-09-12 | — | — | EP | disclosed |
| US-6166040-A | Indole compounds | ELI LILLY AND COMPANY LIMITED (GB) | 2000-12-26 | — | — | US | disclosed |
| WO-2000031074-A2 | INDOLE DERIVATIVES AND THEIR USE AS SEROTONIN RECEPTOR LIGANDS | ELI LILLY AND COMPANY LIMITED (GB) | 2000-06-02 | — | — | WO | disclosed |
| EP-0963983-A1 | Indol-2-ones as serotonin modulators | ELI LILLY AND COMPANY LIMITED (GB) | 1999-12-15 | — | — | EP | disclosed |
| WO-1999058525-A1 | INDOLE DERIVATIVES AS 5-HT2A LIGANDS AND AS SEROTONINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY LIMITED (GB) | 1999-11-18 | — | — | WO | disclosed |
| US-5736534-A | HYPERPROLIFERATIVE DISEASES; INHIBITORS OF PROTEIN-TYROSINE KINASES SUCH AS EPIDERMAL GROWTH FACTOR RECEPTOR; BRAIN, LUNG, BREAST CANCER; PSORIASIS AND BENIGN PROSTATE HYPERPLASIA | PFIZER INC. (US) | 1998-04-07 | — | — | US | disclosed |
| EP-0746554-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| WO-1995023141-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1995-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230127-A1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | IDO1, IDO2, IRF3 | TNF 697/4885RIPK1 1499/4885AR 4472/4885 |
| US-11827602-B2 | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | IDO1, IDO2, IRF3 | TNF 799/4885RIPK1 1591/4885AR 4477/4885 |
| US-20240182414-A1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | IDO1, IDO2, IRF3 | TNF 799/4885RIPK1 1591/4885AR 4477/4885 |
| US-12172959-B2 | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | IDO1, IDO2, IRF3 | TNF 799/4885RIPK1 1591/4885AR 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.